Vaxart was served a grand jury subpoena in July over its controversial role in OWS-funded preclinical study
One-time penny stock player Vaxart made market waves Tuesday morning when the company announced it had dosed the first patients in the Phase I study for its oral Covid-19 vaccine candidate. But underneath those headlines came another piece of news: a grand jury subpoena.
In an 8-K filing with the SEC on Wednesday, Vaxart revealed the US Attorney’s Office for the Northern District of California served the company with the subpoena back in July. The government is probing Vaxart’s participation in a study funded by Operation Warp Speed and the company’s disclosure of the news, as well as grants, warrant transactions, and other financing matters beginning in March 2020, according to the filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.